Drug Profile
Research programme: acute pain therapeutics - Scilex Holding
Alternative Names: D2T patch - Scilex HoldingLatest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Scilex Pharmaceuticals
- Developer Scilex Holding
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute pain
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for preclinical development in Acute pain in Europe (Topical, Patch)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Acute pain in USA (Topical, Patch)
- 22 Mar 2019 Semnur Pharmaceuticals has merged with Scilex Pharmaceuticals to form Scilex Holding